Icomb (Amlodipine, Ramipril)

Amlodipine blocks L‑type calcium channels in vascular smooth muscle, causing vasodilation, while ramipril inhibits the angiotensin‑converting enzyme, decreasing angiotensin II formation and aldosterone secretion. Together they reduce peripheral resistance and blood volume, leading to lower arterial pressure.

The specific dose of Icomb is determined by the prescribing clinician based on the patient’s blood pressure, renal function, and concomitant therapies. Dosage adjustments are individualized, and patients should follow the prescriber’s instructions without altering the regimen on their own.

Icomb is classified as pregnancy category D, indicating evidence of risk to the fetus and it should be avoided unless the potential benefit justifies the risk. Use during lactation is not recommended because ramipril may be excreted in breast milk; alternative therapies should be considered.

To place an order, submit an enquiry on the Icomb product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapies, the amlodipine‑ramipril combination offers complementary mechanisms—vasodilation and renin‑angiotensin blockade—allowing more effective blood‑pressure control at lower individual doses. This can improve adherence and reduce the need for multiple pills, though individual tolerability and cost may influence choice.

Icomb tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Icomb is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

The most serious adverse reactions include angioedema, severe hypotension, and acute kidney injury, particularly in patients with renal impairment or those taking other renin‑angiotensin system blockers. Prompt medical attention is required if swelling of the face, lips, tongue, or difficulty breathing occurs.

Icomb is contraindicated in patients with known hypersensitivity to amlodipine, ramipril, or any excipients, as well as in individuals with a history of angioedema related to ACE‑inhibitor therapy, severe aortic stenosis, or pregnant women. It should also be avoided in patients with significant hepatic impairment without specialist guidance.